Last week CNN.com reported on a study that showed slight improvement of autism symptoms in children that received a single infusion of their own umbilical cord blood. While the study was interesting, the authors were the first to acknowledge the limitations, however, this did not stop the media from misrepresenting the results. Details are explained in this podcast. In addition, a big win this week for precision or personalized medicine: different symptoms and different genetic mutations are linked to different outcomes from different anti-seizure medications.
On March 13th, Dr. Mark Zylka from UNC gave a 60 minute overview of how researchers are using autism-relevant genetic mutations in cells to start to understand the interactions between genetics and thousands of environmental factors on gene expression. He pointed out the convergence of pathways in how genes and these environmental factors worked in the brain, and they included: neuroinflammation, early brain development, turning neurons on and off, and cell signaling. Dr. Valerie Hu from George Washington University commented on the important impact of these results and perspective from her lab studying epigenetically modified genes, like RORA, which also may be sensitive to common chemicals found in our environment. The entire webinar, including the questions that they were able to answer from participants, is found here.
This week’s podcast summarizes a new neural stem cell study and a recent review article on IGF-1 treatment in developmental disorders. IGF stands for Insulin Growth Factor and is essential for generation of new neurons, and shaping and health of existing neurons. Patients with autism spectrum disorder are already starting to be treated with IGF-1, and now there is even more evidence validating it as a target. If you are interested in participating in a research trial at Mt. Sinai School of Medicine using IGF-1, call the Seaver Center at 212-241-0961.